

| Award Principal Investigator | | Award Organization Name | Sponsor Name | Award Name | Award Status | Award Start Date | Award End Date | Funded Amount | Total Award Amount |
|------------------------------|-------------|----------------------------------|---|---|--------------|------------------|----------------|---------------|--------------------|
| Abraham, | Jerold | 110 Pathology | University of Illinois at Chicago | Characteristics of Dust and Risk Factors Associated with the Development of Rapidly Progressive Pneumoconiosis and Progressive Massive Fibrosis | ACTIVE | 16-Jan-2018 | 15-Jan-2021 | 372,370.00 | 372,370.00 |
| Agarwal, | Rinki | 110 OB/GYN | Health Science Center Foundation at Syracuse | Establish PDX ovarian cancer models to test novel nanotherapeutics | ACTIVE | 01-Jan-2018 | 31-Dec-2018 | 25,000.00 | 25,000.00 |
| Bogart, | Jeffrey | 110 Radiology Oncology | Alliance Foundation Trials LLC | Phase II trial of induction immunotherapy with anti-PD-L1 for PD-L1 positive patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent | ACTIVE | 12-Oct-2017 | 11-Oct-2018 | 1.00 | 1.00 |
| Bourmpoulia, | Dimitra | 110 Surgery - Urology | Health Science Center Foundation at Syracuse | Targeting extracellular signaling in cancer | ACTIVE | 01-Jan-2018 | 31-Dec-2018 | 5,000.00 | 5,000.00 |
| Bradshaw, | Deborah | 110 Neurology | Cytokinetics Incorporated | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK 2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS) | ACTIVE | 17-Sep-2017 | 16-Sep-2018 | 1.00 | 1.00 |
| Bratslavsky, | Gennady | 110 Surgery - Urology | MDx Health Incorporated | Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study | ACTIVE | 18-Sep-2017 | 17-Sep-2018 | 1.00 | 1.00 |
| Carkey, | Barbara | 110 Nursing | Health Resources and Services Admin | Behavioral Health Workforce Education and Training (BHWET) Program | ACTIVE | 30-Sep-2017 | 31-Aug-2018 | 432,029.00 | 1,847,192.00 |
| Chan, | Gary | 110 Microbiology | Carol M. Baldwin Breast Cancer Research Fund Inc | The metastatic potential of cytomegalovirus and breast cancer | ACTIVE | 01-Dec-2017 | 30-Nov-2019 | 50,000.00 | 50,000.00 |
| Comito, | Melanie | 110 Pediatrics | St Baldricks Foundation | St. Baldrick's Infrastructure Grant 2017 | ACTIVE | 01-Dec-2017 | 30-Nov-2018 | 58,075.00 | 58,075.00 |
| Domachowske, | Joseph | 110 Pediatrics | Leidos | A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents | ACTIVE | 02-Oct-2017 | 01-Oct-2018 | 105,219.84 | 105,219.84 |
| Faraone, | Stephen | 110 Psychiatry | Shire Pharmaceutical Development Limited | Developing Quality Measures for Adult Attention Deficit Hyperactivity Disorder | ACTIVE | 16-Oct-2017 | 15-Oct-2018 | 75,000.00 | 75,000.00 |
| Faraone, | Stephen | 110 Psychiatry | Shire Pharmaceuticals | Web-Based Continuing Medical Education Program about Screening for Attention Deficit Hyperactivity Disorder (ADHD) in Adults | ACTIVE | 01-Dec-2017 | 30-Nov-2018 | 491,262.00 | 491,262.00 |
| Faraone, | Stephen | 110 Psychiatry | Otsuka Pharmaceutical Development and Commercialization Inc | Developing Quality Measures for Adult Attention Deficit Hyperactivity Disorder | ACTIVE | 25-Dec-2017 | 24-Dec-2018 | 62,500.00 | 62,500.00 |
| Fechtner, | Robert | 110 Ophthalmology | Research to Prevent Blindness | RPB Unrestricted Grant 2018 | ACTIVE | 01-Jan-2018 | 31-Dec-2018 | 115,000.00 | 115,000.00 |
| Fortner, | Christopher | 110 Pediatrics | Vertex Pharmaceuticals Incorporated | A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR . . . | ACTIVE | 01-Dec-2017 | 30-Nov-2018 | 2,000.00 | 2,000.00 |
| Hehnlly, | Heidi | 110 Cell & Developmental Biology | US Army Medical Research Acquisition Activity | PLK1 Spatial Synchronization in prostate epithelial cells during mitosis | ACTIVE | 01-Aug-2017 | 31-Jul-2018 | 121,336.00 | 121,336.00 |
| Horton, | Jason | 110 Surgery - Orthopedics | Carol M. Baldwin Breast Cancer Research Fund Inc | Role of marrow adiposity in skeletal metastasis of breast cancer | ACTIVE | 01-Dec-2017 | 30-Nov-2019 | 50,000.00 | 50,000.00 |
| Huang, | Dongmei | 110 Pediatrics | Sanofi US Services Incorporated | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hecatorol (doxercalciferol capsules) in Pediatric Patients with Chronic Kidney Disease Stages 3 and 4 with Secondary Hyperparathyroidism Not Yet on Dialysis | ACTIVE | 13-Sep-2017 | 12-Sep-2018 | 1.00 | 1.00 |
| Karimi, | Mobin | 110 Microbiology | National Institute of Allergy & Infectious Disease | Novel strategies to separate GVHD from GVT | ACTIVE | 21-Aug-2017 | 31-Jul-2018 | 162,000.00 | 266,383.00 |
| Knutson, | Bruce | 110 Biochemistry | Carol M. Baldwin Breast Cancer Research Fund Inc | Targeting Pol 1 transcription in breast cancer | ACTIVE | 01-Dec-2017 | 30-Nov-2019 | 50,000.00 | 50,000.00 |
| Kotula, | Leszek | 110 Surgery - Urology | Carol M. Baldwin Breast Cancer Research Fund Inc | Abi1 in breast Ca metastases and anti-HER2 therapies | ACTIVE | 01-Dec-2017 | 30-Nov-2019 | 50,000.00 | 50,000.00 |
| Lavelle, | William | 110 Surgery - Orthopedics | Empirical Spine Incorporated | A Concurrently Controlled Study of LimiFlex(TM) Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis with Spinal Stenosis | ACTIVE | 21-Sep-2017 | 20-Sep-2018 | 1.00 | 1.00 |
| Lax, | Michael | 110 Family Medicine | NYS Department of Labor | Worker Healthy & Safety | ACTIVE | 01-Nov-2017 | 31-Mar-2018 | 200,000.00 | 200,000.00 |
| Mollapour, | Mehdi | 110 Surgery - Urology | Health Science Center Foundation at Syracuse | PP5 as a biomarker for tumor development and progression | ACTIVE | 01-Jan-2018 | 31-Dec-2018 | 3,000.00 | 3,000.00 |
| Monteleone, | Philip | 110 Pediatrics | Children's Hospital of Philadelphia | NIH R01 Support: ALTE11C2 Study | ACTIVE | 02-Oct-2017 | 01-Oct-2018 | 1.00 | 1.00 |
| Naqvi, | Muhammad | 110 Medicine | Bristol Myers Squibb Company | Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC | ACTIVE | 29-Aug-2017 | 28-Aug-2018 | 9,250.00 | 9,250.00 |

| | | | | | | | | | |
|--------------|------------|---|---|--|--------|-------------|-------------|------------|--------------|
| Naqvi, | Muhammad | 110 Medicine | BioCin Therapeutics Incorporated | A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma . . . | ACTIVE | 12-Dec-2017 | 11-Dec-2018 | 14,000.00 | 14,000.00 |
| Nieman, | Gary | 110 Surgery - General | Draeger Medical Incorporated | Education Grant: Educating ICU clinicians on research findings concerning lung physiology, mechanical breath profiling, and use of various modes of ventilation with a focus on APRV | ACTIVE | 01-Aug-2017 | 31-Jul-2018 | 55,000.00 | 55,000.00 |
| Oest, | Megan | 110 Surgery - Orthopedics | National Inst of Arthritis Musculoskeletal & Skin | Reducing Post-Radiotherapy Bone Fragility Through Orchestrated Cell Survival | ACTIVE | 01-Aug-2017 | 31-Jul-2018 | 356,400.00 | 1,782,000.00 |
| Paolino, | Kristopher | 110 Medicine | Roche Diagnostics Incorporated | Sample Acquisition/Collection for CIM RD002782 Performance Evaluation: Elecsys Anti-HAV II on the cobas e 601 Immunoassay Analyzer, Version 2 | ACTIVE | 14-Sep-2017 | 13-Sep-2018 | 20,110.88 | 20,110.88 |
| Paolino, | Kristopher | 110 Medicine | Visterra Incorporated | Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A . . . | ACTIVE | 29-Nov-2017 | 28-Nov-2018 | 1.00 | 1.00 |
| Perl, | Andras | 110 Medicine | EMD Serono Incorporated | A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) | ACTIVE | 04-Aug-2017 | 03-Aug-2018 | 15,500.00 | 15,500.00 |
| Perl, | Andras | 110 Medicine | Celgene Corporation | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus | ACTIVE | 11-Aug-2017 | 10-Aug-2018 | 1.00 | 1.00 |
| Perl, | Andras | 110 Medicine | Aurinia Pharmaceuticals Incorporated | A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis | ACTIVE | 29-Aug-2017 | 28-Aug-2018 | 1.00 | 1.00 |
| Perl, | Andras | 110 Medicine | NYS Department of Health | Lupus, Autoimmunity, Inflammation and Immune Health Center of Excellence (LACE) | ACTIVE | 31-Dec-2017 | 30-Dec-2019 | 349,444.00 | 349,444.00 |
| Pignoni, | Francesca | 110 Ophthalmology | National Eye Institute | Neural versus non-neural fate choice in the developing eye epithelium | ACTIVE | 01-Sep-2017 | 31-May-2018 | 364,500.00 | 1,458,000.00 |
| Poiesz, | Bernard | 110 Medicine | Calithera Biosciences Incorporated | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) | ACTIVE | 25-Oct-2017 | 24-Oct-2018 | 1.00 | 1.00 |
| Sachdeva, | Ramesh | 110 Senior Vice President and Dean of the College of Medicine | Health Research Inc | State Innovation Model: Round Two of Funding for Design and Test Assistance | ACTIVE | 01-Jan-2018 | 31-Jan-2019 | 175,000.00 | 175,000.00 |
| Sanders, | Amy | 110 Neurology | Janssen Research and Development LLC | A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer's Dementia | ACTIVE | 15-Nov-2017 | 24-Feb-2023 | 3,000.00 | 3,000.00 |
| Setter, | Kevin | 110 Surgery - Orthopedics | OrthoSpace Limited | A prospective, single blinded, multi-center, randomized, controlled, pivotal study to assess the safety and effectiveness of the InSpace(TM) device for treatment of full thickness Massive Rotator Cuff Tears | ACTIVE | 01-Sep-2017 | 31-Aug-2018 | 22,440.00 | 22,440.00 |
| Setter, | Kevin | 110 Surgery - Orthopedics | OneDirect Health Network Incorporated | A Prospective, Single Center, Randomized Stud to Evaluate the Effectiveness of the T-rex (Total Range Exerciser) Compared to Standard Physical Therapy After Arthroscopic Shoulder Surgery for Rotator Cuff Repair | ACTIVE | 20-Oct-2017 | 19-Oct-2018 | 5,500.00 | 5,500.00 |
| Sheikh, | M | 110 Pharmacology | Carol M. Baldwin Breast Cancer Research Fund Inc | Development of a natural product for breast cancer treatment | ACTIVE | 01-Dec-2017 | 30-Nov-2019 | 50,000.00 | 50,000.00 |
| Suryadevara, | Manika | 110 Pediatrics | Janssen Research and Development LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized. . . | ACTIVE | 07-Dec-2017 | 06-Dec-2018 | 1.00 | 1.00 |
| Suryadevara, | Manika | 110 Pediatrics | Janssen Research and Development LLC | A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection | ACTIVE | 13-Feb-2018 | 30-Oct-2021 | 1.00 | 1.00 |
| Tallarico, | Richard | 110 Surgery - Orthopedics | VertiFlex Incorporated | Postmarket Superior Spacer Registry for Evaluation of Superior Spacer (PRESS) | ACTIVE | 26-Jan-2018 | 25-Jan-2019 | 1.00 | 1.00 |
| Turk, | Margaret | 110 Rehabilitation Medicine | University of South Carolina | Coordinating Center for Research to Promote the Health of Children with Birth Defects and People with Developmental and Other Disabilities | ACTIVE | 30-Sep-2017 | 29-Sep-2018 | 77,490.00 | 77,490.00 |
| Viapiano, | Mariano | 110 Physiology | US Army Medical Research Acquisition Activity | Engineering T Cells Against the Tumor Extracellular Matrix for Enhanced Immunotherapy of Mesthelioma | ACTIVE | 01-Aug-2017 | 14-Aug-2018 | 296,100.00 | 296,100.00 |
| Wang, | Guirong | 110 Surgery - General | National Science Foundation | SCH: INT: Collaborative Research: Crowd in Action: Human-Centric Privacy-Preserving Data Analytics for Environmental Public Health | ACTIVE | 01-Sep-2017 | 31-Aug-2018 | 259,000.00 | 259,000.00 |
| Weiner, | Leonard | 110 Pediatrics | Merck Sharp and Dohme Corporation | A Phase III randomized, active-comparator-controlled clinical trial to study the safety and efficacy of MK-1986 (tedizolid phosphate) and comparator, in subjects 3 months to <12 years of age with Acute Bacterial Skin and Skin Structure. . . | ACTIVE | 01-Aug-2017 | 31-Jul-2018 | 1.00 | 1.00 |
| Weiner, | Leonard | 110 Pediatrics | Merck Sharp and Dohme Corporation | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects with Complicated Urinary Tract . . . | ACTIVE | 20-Nov-2017 | 19-Nov-2018 | 1.00 | 1.00 |
| Weiner, | Leonard | 110 Pediatrics | Merck Sharp and Dohme Corporation | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects . . . | ACTIVE | 20-Nov-2017 | 19-Nov-2018 | 1.00 | 1.00 |

| | | | | | | | | | |
|---------------|---------|------------------|--|---|--------|-------------|-------------|-----------|-----------|
| Weiner, | Leonard | 110 Pediatrics | Merck Sharp and Dohme Corporation | A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II | ACTIVE | 05-Jan-2018 | 04-Jan-2019 | 1.00 | 1.00 |
| Weinstock, | Ruth | 110 Medicine | Jaeb Center for Health Research Incorporated | CGM Intervention in Teens and Young Adults with T1D (CITY) | ACTIVE | 01-Sep-2017 | 31-Dec-2019 | 5,500.00 | 5,500.00 |
| Weinstock, | Ruth | 110 Medicine | Mylan Incorporated | A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients | ACTIVE | 07-Dec-2017 | 06-Dec-2018 | 5,050.00 | 5,050.00 |
| Wojcikiewicz, | Richard | 110 Pharmacology | University of Virginia | Role of EZH2 in myelofibrosis | ACTIVE | 01-Sep-2017 | 31-May-2018 | 28,125.00 | 28,125.00 |